GoKawiilGray-market peptide BPC-157 surges in popularity despite scant human safety data
A Verge newsletter examines BPC-157, an unapproved 'body protection compound' peptide popularized as part of the so-called Wolverine stack for injury recovery. A 2025 systematic review found only 35 preclinical studies and a single human clinical study on the substance, even as it racked up over 50 million YouTube and TikTok views in 2024 and a reported 1,600 percent rise in US web searches over five years.
GoKawiil's interpretation of the reporting above, not reported fact.
The gap between surging consumer interest and minimal clinical evidence suggests many users are self-administering an unregulated substance with no official safety or dosage guidance. Because the activity exists in a legal gray area, reliable usage statistics are hard to obtain, which could make it difficult for regulators or doctors to assess real-world risks until problems surface.
- BPC-157 has only one human clinical study despite widespread informal use.
- Online interest in the peptide has grown dramatically, with search and video view counts rising sharply.
- Lack of regulation and data makes it hard to quantify real-world usage or safety risks.
Source: theverge.com — Victoria Song, 2026-10-07
Published there as: “The scariest thing about gray-market peptides is how little we know”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.